DEPLOYDatabase

Company

Intuitive Surgical

Dominant surgical-robotics maker (NASDAQ: ISRG; founded 1995, Sunnyvale CA) of the [da Vinci](/models/intuitive-da-vinci) teleoperated surgical robots and the…

Track Intuitive SurgicalGet notified of verified changes
Founded
1995
HQ
Sunnyvale, California, USA
Status
public (NASDAQ: ISRG)
Models
2
Deployments
3
Patents
3

Verified profile

  • 7

    Sources on record

  • 1

    Tracked changes

  • Updated 1 month ago

    Last verified change

Overview

Dominant surgical-robotics maker (NASDAQ: ISRG; founded 1995, Sunnyvale CA) of the da Vinci teleoperated surgical robots and the Ion robotic bronchoscopy system; 11,000+ da Vinci installed worldwide.

Verified record

Verified deployments
3 deployments on file
Active incidents
46 incidents on file

DEPLOY Intelligence

Market intelligence for physical AI

Analyst-grade signals, competitive tracking, and investment context across the global physical AI landscape. Launching 2026.

Current platform

Ion Endoluminal System

Intuitive Surgical's Ion Endoluminal System is a robotic-assisted bronchoscopy platform for minimally invasive biopsy of peripheral lung nodules. It uses an ultra-thin, shape-sensing maneuverable catheter with PlanPoint CT-based airway planning to reach lesions deep in the peripheral lung. FDA 510(k) cleared in February 2019 and commercially deployed across US hospitals, with subsequent AI and advanced-imaging integration clearances.

surgicalView model →

Current platform

da Vinci (and Ion)

Intuitive Surgical (NASDAQ: ISRG; founded 1995, Sunnyvale, California) is the dominant incumbent and verified gold standard of surgical robotics. Its da Vinci platform spans the multi-port X and Xi systems, the SP single-port system, and the fifth-generation da Vinci 5, which the FDA cleared via 510(k) on March 14, 2024 with a headline Force Feedback sensing feature, alongside the Ion endoluminal robotic bronchoscopy system cleared in February 2019. As of its SEC Form 10-Q for the quarter ended March 31, 2026, the verified installed base was 11,395 da Vinci systems, up 12 percent year over year and including 1,464 da Vinci 5 units, plus 1,041 Ion systems, up 22 percent, with worldwide procedures growing about 17 percent. Surgical robotics sits in the registry as a deliberate axis-extension: physical AI operating in the medical regulatory regime, where FDA clearance is the verified gating event for maturity, and Intuitive clears it across multiple platforms and generations, placing it at production maturity. On AI substance, da Vinci is a master-slave teleoperated system with shipped analytics-grade AI such as Case Insights and machine-vision interface features, and Force Feedback is a shipped sensing feature rather than autonomy; autonomous suturing and tissue manipulation via vision-language models are research demonstrations on da Vinci hardware, not shipped features, and the 4,000-mile telesurgery demonstration is investigational. The widely cited 43-percent-less-force figure is preclinical and marketing-sourced rather than an outcomes-verified clinical result.

surgicalView model →

Relationships

Current leadership (3)

Founders (3)

Board (3)

Former / Previously (4)

Safety record

41 recalls and 5 incidents on record (1 catastrophic, 3 critical, 35 serious, 6 moderate, 1 minor). Most recent: Jun 2026.

catastrophic
1
critical
3
serious
35
moderate
6
minor
1
recall
41
regulatory action
2
injury
2
other
1

Most recent: Jun 2026

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Incidents affecting Intuitive Surgical (46)

Includes incidents linked directly to this company, to its models, or to deployments of its models or under its operation. Retracted incidents are excluded from this view but remain reachable at their canonical URLs.

Operated deployments (3)

Operator customers (1)

Recent coverage

Intuitive Surgical in third-party press

Peer companies